Shares of Sun Pharmaceutical Industries Ltd surged nearly 9 per cent to Rs 1,766 on Monday after the company announced an agreement to acquire Organon & Co. in an all‑cash deal valued at USD 11.75 billion. The proposed acquisition, priced at USD 14 per Organon share, marks Sun Pharma’s biggest overseas buy and positions the Indian drugmaker as a top‑10 global player in biosimilars, the deal also strengthens its presence in women’s health and established branded generics across key global markets.
Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021, Sun Pharma said in an exchange filing.
A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimilars, commercialised across 140 countries, with the U.S., Europe, China, Canada, and Brazil among its largest markets. This global footprint is supported by six manufacturing facilities across the European Union and emerging markets, the filing said.
The proposed acquisition of Organon is aligned with Sun Pharma’s strategy of growing its Innovative Medicines business. The combined company becomes a stronger player in Established Brands /Branded Generics business. The deal also enables Sun Pharma’s entry into biosimilars as a Top-10 global player. Organon’s portfolio, global footprint and strong stakeholder relationships shall complement Sun Pharma’s existing strengths and enhance long‑term value creation.
(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money related decisions.)
